Want to see IN:INNOVACAP full AI Analyst Report?
Top Page
Innova Captab Limited
(INNOVACAP)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹1,220.00
▲(27.42% Upside)
Action:Reiterated
Date:08/11/26
The score is driven primarily by solid financial performance (strong growth, healthy profitability, and improved leverage) but is held back meaningfully by weak free-cash-flow conversion. Technicals are supportive with a steady uptrend and neutral momentum, while valuation is a notable headwind due to the high P/E and very low dividend yield.
Positive Factors
Strong Revenue Growth
Strong and accelerating revenue growth indicates expanding demand for Innova Captab’s pharmaceutical manufacturing and finished-dose offerings. If sustained, this scale can improve customer reach, support operating leverage, and strengthen the company’s ability to reinvest in capacity and product development.
Negative Factors
Weak Free-Cash-Flow Conversion
Repeatedly negative free cash flow means reported growth and earnings have not consistently converted into cash available for reinvestment, debt reduction, or shareholder returns. Modest recent improvement is encouraging, but continued weak conversion could constrain self-funded expansion and raise execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Strong and accelerating revenue growth indicates expanding demand for Innova Captab’s pharmaceutical manufacturing and finished-dose offerings. If sustained, this scale can improve customer reach, support operating leverage, and strengthen the company’s ability to reinvest in capacity and product development.
Read all positive factors
Innova Captab Limited (INNOVACAP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹65.56B
Dividend Yield0.17%
Average Volume (3M)6.64K
Price to Earnings (P/E)42.4
Beta (1Y)0.87
Revenue Growth34.47%
EPS Growth20.42%
CountryIN
Employees1,600
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)26.91
Shares Outstanding57,224,930
10 Day Avg. Volume6,717
30 Day Avg. Volume6,644
Financial Highlights & Ratios
PEG Ratio2.83
Price to Book (P/B)3.62
Price to Sales (P/S)2.46
P/FCF Ratio114.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)33.05
Revenue Forecast (FY)₹20.19B
Innova Captab Limited Business Overview & Revenue Model
Company Description
Innova Captab Limited, established in Panchkula, India, in 2005, operates as a comprehensive pharmaceutical enterprise. Its operations encompass the full spectrum of drug development, from research and development and manufacturing to distribution...
How the Company Makes Money
Innova Captab Limited primarily makes money by manufacturing and selling pharmaceutical finished dosage formulations. Its revenue model generally includes: (1) Sales of finished dosage products: income earned from supplying its own or customer-spe...
Innova Captab Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.49B | 16.04B | 12.44B | 10.77B | 9.26B | 8.00B |
| Gross Profit | 3.95B | 5.23B | 4.30B | 3.42B | 2.35B | 1.73B |
| EBITDA | 2.67B | 2.10B | 1.86B | 1.67B | 1.23B | 987.68M |
| Net Income | 1.54B | 1.41B | 1.28B | 943.45M | 679.54M | 639.53M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 18.37B | 15.80B | 13.21B | 10.19B | 5.75B |
| Cash, Cash Equivalents and Short-Term Investments | 682.50M | 451.54M | 652.81M | 840.92M | 70.25M | 8.75M |
| Total Debt | 0.00 | 3.44B | 3.38B | 2.45B | 2.37B | 1.99B |
| Total Liabilities | -10.91B | 7.47B | 6.21B | 4.90B | 6.93B | 3.67B |
| Stockholders Equity | 10.91B | 10.91B | 9.59B | 8.31B | 2.77B | 2.09B |
Cash Flow | ||||||
| Free Cash Flow | -125.34M | 343.39M | -1.09B | -1.41B | -118.67M | -209.85M |
| Operating Cash Flow | 297.19M | 1.03B | 638.44M | 1.46B | 671.24M | 588.98M |
| Investing Cash Flow | -354.74M | -1.10B | -1.52B | -4.99B | -908.43M | -1.88B |
| Financing Cash Flow | -92.25M | -51.35M | 915.33M | 3.61B | 270.92M | 1.25B |
Innova Captab Limited Technical Analysis
Positive
957.45
Price Trends
1028.54
Positive
954.32
Positive
826.18
Positive
Market Momentum
42.37
Negative
60.87
Neutral
62.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INNOVACAP, the sentiment is Positive. The current price of 957.45 is below the 20-day moving average (MA) of 1100.13, below the 50-day MA of 1028.54, and above the 200-day MA of 826.18, indicating a bullish trend. The MACD of 42.37 indicates Negative momentum. The RSI at 60.87 is Neutral, neither overbought nor oversold. The STOCH value of 62.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INNOVACAP.
Innova Captab Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹76.78B | 53.60 | ― | 0.22% | 20.59% | 27.16% | |
63 Neutral | ₹65.56B | 42.37 | ― | 0.17% | 34.47% | 20.42% | |
61 Neutral | ₹50.91B | 577.19 | ― | 16.67% | 10.83% | -89.82% | |
57 Neutral | ₹37.84B | 11.99 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹63.54B | 41.49 | ― | 0.17% | 9.48% | 50.50% | |
50 Neutral | ₹42.54B | 58.07 | ― | 0.02% | 16.70% | 18.73% |
* General Sector Average
IN:INNOVACAP
Innova Captab Limited
1,141.25
282.25
32.86%
IN:BLISSGVS
Bliss Gvs Pharma Limited
686.35
535.47
354.91%
IN:GUFICBIO
Gufic Biosciences Limited
425.00
60.94
16.74%
IN:MOREPENLAB
Morepen Laboratories Limited
106.25
52.92
99.23%
IN:ORCHPHARMA
Orchid Pharma Limited
988.90
280.00
39.50%
IN:UNICHEMLAB
Unichem Laboratories Limited
520.60
16.40
3.25%
Innova Captab Limited Corporate Events
Innova Captab Board Clears Revised Audited FY26 Results
Aug 23, 2026
Innova Captab Limited has notified the stock exchanges that its board has approved revised audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, following a late-night board meeting on Augus...
Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion
Aug 22, 2026
Innova Captab Limited’s board has approved the revision of its standalone and consolidated financial statements for the financial year ended 31 March 2026, including updated audited results, balance sheets, cash flow statements, and independ...
Innova Captab Revises FY26 Results and Clears Baddi Capacity Expansion
Aug 22, 2026
Innova Captab Limited’s board has approved a revision of the company’s standalone and consolidated financial statements for the fiscal year 2025-26, including updated audited results, balance sheets, cash flow statements and auditor re...
Innova Captab Extends Trading Window Closure Ahead of Revised FY26 Results
Aug 13, 2026
Innova Captab Limited has announced that its trading window for dealing in the company’s securities will remain closed for all designated persons and their immediate relatives, in line with SEBI’s Prohibition of Insider Trading Regulat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.